Advertisement

Advertisement
Kidney Cancer
Immunotherapy

Study Supports Pembrolizumab Plus Axitinib in Previously Untreated Advanced Renal Cell Carcinoma

Extended analysis of the phase III KEYNOTE-426 study upholds pembrolizumab plus axitinib as a preferred front-line regimen over sunitinib in patients with advanced sporadic renal cell carcinoma. These updated results were presented at the ASCO20 Virtual Scientific Program by Elizabeth R. Plimack, MD, Chief of the Division of Genitourinary Medical Oncology and Director of Genitourinary Clinical Research at Fox Chase Cancer Center, Philadelphia.

 

Multiple Myeloma
Immunotherapy

Elotuzumab Fails to Add Benefit in Newly Diagnosed High-Risk Myeloma

The addition of elotuzumab to a standard three-drug induction regimen did not improve outcomes in patients with high-risk multiple myeloma enrolled in the randomized phase II SWOG S1211 trial, according to findings reported during the ASCO20 Virtual Scientific Program by Saad Zafar Usmani, MD, FACP, of Levine Cancer Institute/Atrium Health, Charlotte, North Carolina.

 

Gynecologic Cancers

Two Studies Report Secondary Surgery Extends Survival in Recurrent Ovarian Cancer

Two phase III trials provide support for secondary cytoreductive surgery in women with recurrent ovarian cancer, with the caveats that patient selection is key and the surgery should be performed at sites of excellence. The results of the DESKTOP III and SOC1 trials, both presented during the ASCO20 Virtual Scientific Program, found cytoreductive surgery improved outcomes in selected patients.

 


Advertisement
Prostate Cancer

Novel Androgen-Deprivation Therapy With Relugolix Causes Fewer Cardiac Events Than Leuprolide in Advanced Prostate Cancer

Men with prostate cancer on androgen-deprivation therapy are usually treated with leuprolide, a long-acting injectable luteinizing hormone-releasing hormone (LHRH) agonist requiring an every-3-month injection, but it may be possible for ADT to be delivered by a daily oral treatment, pending regulatory approval. In the phase III HERO study, oral relugolix, given daily, was superior to leuprolide for achieving testosterone suppression in men with advanced prostate cancer who required androgen-deprivation therapy, as reported during the ASCO20 Virtual Scientific Program by Neal D. Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, South Carolina, and published online in The New England Journal of Medicine to coincide with the presentation.

 

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




Breast Cancer

Cynthia X. Ma, MD, PhD, on Breast Cancer: Neoadjuvant Endocrine Treatment for ER-Positive, HER2-Negative Disease

Lung Cancer

SIR 2020 Virtual: Transarterial Chemoperfusion for Patients With Mesothelioma

A novel treatment for patients with advanced mesothelioma is safe and effective and may improve the quality of life for patients who have few treatment options, according to a research abstract presented during a virtual session of the Society of Interventional Radiology (SIR) 2020 Annual...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Colorectal Cancer

Alberto F. Sobrero, MD, on Colon Cancer: Adjuvant Oxaliplatin and Fluoropyrimidine-Based Therapy for Stage III Disease

Prostate Cancer
Pancreatic Cancer
Lymphoma

FDA Pipeline: Agents for the Treatment of Prostate and Pancreatic Cancers, Marginal Zone Lymphoma

Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to relugolix for the treatment of advanced prostate cancer; Fast Track designation to a radioimmunotherapeutic treatment for marginal zone lymphoma; and Orphan Drug designation to a novel monoclonal antibody for...

Lymphoma

Efficacy Outcomes With C-MTX in Newly Diagnosed Patients With Pediatric T-Cell Lymphoblastic Lymphoma

As reported in the Journal of Clinical Oncology by Hayashi et al, the Children’s Oncology Group AALL0434 study has shown “excellent” outcomes with Capizzi-based methotrexate/pegaspargase (C-MTX) treatment in patients with newly diagnosed pediatric T-cell lymphoblastic lymphoma (T-LL). The addition...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Leukemia

Abhishek Maiti, MBBS, on AML: Decitabine and Venetoclax vs Intensive Chemotherapy

Issues in Oncology

Study Links Financial Hardship to More Emergency Room Visits, Less Preventive Care Among Cancer Survivors

A new study has found higher medical and nonmedical financial hardships are independently associated with more emergency department visits, lower receipt of some preventive services, and worse self-rated health in cancer survivors. The authors of the study warn that as health-care costs grow, unmet ...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...